<DOC>
	<DOC>NCT00195689</DOC>
	<brief_summary>The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis</brief_summary>
	<brief_title>Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject completed study M02518 or M02570 Subject prematurely discontinued study M02518 or M02570 Female subject who is pregnant or breastfeeding or considering becoming pregnant Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>